Trial reportChild psychiatry and human development2012
A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders.
Trial report in Child psychiatry and human development, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Adverse event monitoring, assessment, and reporting in nutraceutical and phytoceutical trials for pediatric neuropsychiatric conditions: A systematic review.Journal of psychopharmacology (Oxford, England) · 2025Pooled it
- Impact of antipsychotics in children and adolescents with autism spectrum disorder: a systematic review and meta-analysis.Health and quality of life outcomes · 2021Pooled it
- Predictors of placebo response in pharmacological and dietary supplement treatment trials in pediatric autism spectrum disorder: a meta-analysis.Translational psychiatry · 2015Pooled it
- A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial.Child psychiatry and human development · 2014Trial
- Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial.Paediatric drugs · 2013Trial
- Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial.Psychopharmacology · 2013Trial
- Natural products modulate social behavior and gut microbiota in a valproic acid-induced zebrafish model of autism spectrum disorder.Biomolecules & biomedicine · 2026Article
- Medicinal Plants for Child Mental Health: Clinical Insights, Active Compounds, and Perspectives for Rational Use.Children (Basel, Switzerland) · 2025Review
- Review
- Pharmacological effects and therapeutic potential of natural compounds in neuropsychiatric disorders: An update.Frontiers in pharmacology · 2022Review
- Paving Plant-Food-Derived Bioactives as Effective Therapeutic Agents in Autism Spectrum Disorder.Oxidative medicine and cellular longevity · 2021Article
- Neuroprotective Effects of Quercetin in Pediatric Neurological Diseases.Molecules (Basel, Switzerland) · 2020Review
- Article
- Efficacy and safety of ginkgo preparations for attention deficit hyperactivity disorder: a systematic review protocol.BMJ open · 2018Article
- Herbal Medicine Treatment for Children with Autism Spectrum Disorder: A Systematic Review.Evidence-based complementary and alternative medicine : eCAM · 2017Review
- Complementary and Alternative Therapies for Autism Spectrum Disorder.Evidence-based complementary and alternative medicine : eCAM · 2015Review
- A Systematic Review and Meta-Analysis of Ginkgo biloba in Neuropsychiatric Disorders: From Ancient Tradition to Modern-Day Medicine.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Review of the pharmacotherapy of irritability of autism.Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ginkgo biloba has been reported to affect the neurotransmitter system and to have antioxidant properties that could impact the pathogenesis of Autism Spectrum Disorder. Based on these studies, we decided to assess the effectiveness of Ginkgo biloba extract (Ginko T.D., Tolidaru, Iran) as an adjunctive agent to risperidone in the treatment of autism. Forty-seven outpatients with a DSM-IV-TR diagnosis of autism ages between 4 and 12 years were assigned to this double blinded clinical trial and were randomly divided into two groups. One group received risperidone plus Ginko T.D and the other received risperidone plus placebo. The dose of risperidone was 1-3 mg/day and the dose of Ginko T.D. was 80 mg/day for patients under 30 kg and 120 mg/day for patients above 30 kg. Patients were assessed using Aberrant Behavior Checklist-Community (ABC-C) rating scale and the side effect check list every 2 weeks until the endpoint. None of the 5 subscales of ABC-C rating scale showed significant differences between the two groups. Incidents of side effects were not significantly different between the two groups. Adding Ginkgo biloba to risperidone did not affect the treatment outcome of ADs. Nevertheless, further observations are needed to confirm this result.
Indexed as
Identifiers
22392415What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.